Frustration is growing among anti-abortion advocates regarding the FDA’s recent approval of a second version of Mifepristone, a medication used in abortions. After President Trump’s campaign promises to let states decide on abortion policies, these advocates are pressuring him to take more decisive action to restrict Mifepristone’s availability.
Despite the pressures, there hasn’t been much movement in that direction yet.
A letter to a group of GOP State Attorneys General indicated that the FDA is examining data concerning the safety of Mifepristone to determine how it can be safely distributed. On September 19, Robert F. Kennedy Jr., the Secretary of Health and Human Services, along with FDA Commissioner Marty McCurry, stated their commitment to ensuring women’s health through a comprehensive investigation.
This news was met with cautious optimism from right-leaning lawmakers and activists, who are urging the FDA to swiftly reverse regulatory changes that could facilitate easier access to Mifepristone. Yet, news emerged that Evita Solutions is set to become the third company approved to manufacture and sell Mifepristone.
“The FDA was supposed to conduct a thorough safety review of chemical abortion drugs, but they instead approved them for distribution, undermining trust in the agency’s leadership,” critics lamented.
During a confirmation hearing, Makary emphasized the need for a coalition of experts to evaluate the ongoing data related to Mifepristone.
A letter from Holy to McCurry sought clarity on the drug approval process and questioned McCurry’s personal involvement in the decision. “This choice seems to disregard scientific evidence in favor of a questionable ideological agenda,” Holy remarked.
He also pointed out that any potential safety measures might not apply to the new generic versions of the drug, rendering safety reviews somewhat irrelevant.
Separately, a group within the House is urging Kennedy to dismiss FDA leaders who played a role in approving the drug, citing concerns over misconduct impacting the sanctity of life.
The FDA, however, defends its approval process as rooted in science rather than political motivations. White House press director Karoline Leavitt reaffirmed that a secretary must approve drug applications if they meet certain criteria.
As of now, the White House has largely targeted easy victories concerning abortion funding and access, with sixteen states implementing abortion bans. Nevertheless, mifepristone remains accessible, as medical professionals in states where abortion is protected can prescribe it via telehealth and mail it to patients.
This situation has sparked legal challenges regarding laws that protect doctors from prosecution in states with stricter abortion laws. Anti-abortion groups are urging the FDA to enforce stricter regulations against mailing the drug, which had seen relaxed rules during the Covid-19 pandemic.
According to the anti-abortion group Susan B. Anthony Prolife America, Trump believes in states’ rights to enact protective measures for life, which they argue is undermined by the abortion industry. Kelsey Pritchard, the group’s state communications director, expressed impatience for the FDA to prioritize safety reviews and reverse lenient regulations.
She emphasized the need for the FDA to act quickly in changing its course. Pritchard feels the acceptance of the second generic version of Mifepristone contradicts the administration’s stated priorities.
Kristi Hamrick, a spokesperson for Life of America for Students, said there’s an understanding of lawmakers’ calls for changes at the FDA, advocating for transparency and thorough reviews regarding abortion drugs.
On Friday, a coalition of anti-abortion advocates, lawmakers, and religious figures urged the FDA to retract its recent approval and remove Mifepristone from the market. They pointed out that this approval directly contradicts Secretary Kennedy’s assurances regarding the safety of abortion drugs.
